40357-87-7

Basic information

• Product Name: 4-Hydroxy-1-Methyl-1h-pyridin-2-one
• Synonyms: 4-Hydroxy-1-Methyl-1h-pyridin-2-one;4-Hydroxy-1-Methyl-2-pyridone;4-Hydroxy-1-methylpyridin-2(1H)-one;1,2-dihydro-4-hydroxy-1-methyl-2-oxopyridine;4-hydroxy-1-methylpyridin-2-one
• CAS NO: 40357-87-7
• Molecular Formula: C₆H₇NO₂
• Molecular Weight: 125.12528
• Mol File: 40357-87-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 266.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.309±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 4-Hydroxy-1-Methyl-1h-pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy-1-Methyl-1h-pyridin-2-one(40357-87-7)
• EPA Substance Registry System: 4-Hydroxy-1-Methyl-1h-pyridin-2-one(40357-87-7)

Safety Data

• Hazardous Substances Data: 40357-87-7(Hazardous Substances Data)

Usage

Description

4-Hydroxy-1-Methyl-1h-pyridin-2-one, also known as 4-Hydroxy-1-methyl-2-pyridone, is an organic compound with the molecular formula C6H7NO2. It is a derivative of pyridinone, featuring a hydroxyl group and a methyl group attached to the pyridine ring. 4-Hydroxy-1-Methyl-1h-pyridin-2-one is known for its potential applications in various fields, particularly in the pharmaceutical industry, due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-1-Methyl-1h-pyridin-2-one is used as a reactant for the synthesis of 3-deaza-3-halouracil nucleosides, which exhibit cytostatic activity in three cancer cell lines. These nucleosides have the potential to be developed into effective anti-cancer drugs, making this compound a valuable starting material in the development of novel cancer treatments.

Upstream product

• 53937-03-4 N‐methyl‐4‐benzyloxy‐2‐pyridone 
• 53937-02-3 4-(benzyloxy)pyridin-2(1H)-one 
• 626-03-9 3-deazauracil 
• 77-78-1 dimethyl sulfate 
• 53937-02-3 4‐benzyloxy‐2‐hydroxy‐pyridine 

Downstream Products

• 41759-19-7 4-methoxy-1-methyl-2-pyridone 
• 1613057-54-7 3-(4-butylphenyl)-4-hydroxy-1-methylpyridin-2(1H)-one 
• 1613057-55-8 3-(3,5-dimethylphenyl)-4-hydroxy-1-methylpyridin-2(1H)-one 
• 1613057-57-0 3-(biphenyl-4-yl)-4-hydroxy-1-methylpyridin-2(1H)-one 
• 1613057-58-1 4-hydroxy-1-methyl-3-o-tolyl-pyridin-2(1H)-one 
• 92-52-4 biphenyl 
• 1613057-52-5 4-hydroxy-1-methyl-3-phenylpyridin-2(1H)-one 
• 1613057-53-6 C₁₂H₁₂N₂O₄ 

Relevant articles and documents

-

-

TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships

The discovery of new antibacterial agents with novel mechanisms of action is necessary to overcome the problem of bacterial resistance that affects all currently used classes of antibiotics. Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically validated targets of the fluoroquinolone antibiotics which exert their antibacterial activity through inhibition of the catalytic subunits. Inhibition of these targets through interaction with their ATP sites has been less clinically successful. The discovery and characterization of a new class of low molecular weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presented. The benzimidazole ureas are dual targeting inhibitors of both enzymes and possess potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.